Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: a 15-year follow-up of the Chinese Multi-provincial Cohort Study.

[1]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[2]  A. RossNaylor.  Letter by Naylor Regarding Article, “Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association” , 2011 .

[3]  Moshe Levi,et al.  Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[4]  S. Teelucksingh,et al.  Association of low serum creatinine, abnormal lipid profile, gender, age and ethnicity with type 2 diabetes mellitus in Trinidad and Tobago. , 2011, Diabetes research and clinical practice.

[5]  M. Fornage,et al.  Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[6]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[7]  Nicholas J Wareham,et al.  Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. , 2009, Journal of the American College of Cardiology.

[8]  K. Kotseva,et al.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[9]  D. Arveiler,et al.  Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007. , 2009, Archives of cardiovascular diseases.

[10]  A. Mokdad,et al.  Hypertriglyceridemia and its pharmacologic treatment among US adults. , 2009, Archives of internal medicine.

[11]  HisatomiArima,et al.  LDL Cholesterol and the Development of Stroke Subtypes and Coronary Heart Disease in a General Japanese Population , 2009 .

[12]  S. Ibayashi,et al.  LDL Cholesterol and the Development of Stroke Subtypes and Coronary Heart Disease in a General Japanese Population: The Hisayama Study , 2009, Stroke.

[13]  J. Hebebrand,et al.  Contribution of Obesity and Abdominal Fat Mass to Risk of Stroke and Transient Ischemic Attacks , 2008, Stroke.

[14]  J. Liao.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2008, Current atherosclerosis reports.

[15]  S. Grundy,et al.  Ten-year cardiovascular disease risk of metabolic syndrome without central obesity in middle-aged chinese. , 2007, The American journal of cardiology.

[16]  Y. Li,et al.  Blood lipid profile and prevalence of dyslipidemia in Chinese adults. , 2007, Biomedical and environmental sciences : BES.

[17]  K. Yamagishi,et al.  Metabolic Syndrome and the Risk of Ischemic Heart Disease and Stroke Among Japanese Men and Women , 2007, Stroke.

[18]  S. Grundy,et al.  Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. , 2007, American heart journal.

[19]  P. Sorlie,et al.  Trends in Serum Lipids and Lipoproteins of Adults 1960-2002 , 2006 .

[20]  Jiang He,et al.  Are waist circumference and body mass index independently associated with cardiovascular disease risk in Chinese adults? , 2005, The American journal of clinical nutrition.

[21]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[22]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[23]  Jing Liu,et al.  Cardiovascular disease risk factor levels and their relations to CVD rates in China - results of Sino-MONICA project , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[24]  Dong Zhao,et al.  Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. , 2004, JAMA.

[25]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[26]  M. Pfeffer,et al.  Coronary Heart Disease in Patients With Low LDL-Cholesterol: Benefit of Pravastatin in Diabetics and Enhanced Role for HDL-Cholesterol and Triglycerides as Risk Factors , 2002, Circulation.

[27]  Y. Friedlander,et al.  Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. , 2001, Atherosclerosis.

[28]  Jing Liu,et al.  Sino-MONICA Project: A Collaborative Study on Trends and Determinants in Cardiovascular Diseases in China, Part I: Morbidity and Mortality Monitoring , 2001, Circulation.

[29]  D. Jacobs,et al.  Plasma triglyceride level and mortality from coronary heart disease. , 1993, The New England journal of medicine.

[30]  F. Cambien,et al.  Is the level of serum triglyceride a significant predictor of coronary death in "normocholesterolemic" subjects? The Paris Prospective Study. , 1986, American journal of epidemiology.

[31]  W. Kannel,et al.  Lipoproteins, cardiovascular disease, and death. The Framingham study. , 1981, Archives of internal medicine.

[32]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[33]  Y. Kiyohara.  [The Hisayama Study]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.

[34]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[35]  D. Gordon,et al.  High-Density Lipoprotein Cholesterol and Cardiovascular Disease , 2005 .

[36]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[37]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[38]  D. Gordon,et al.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.